{
  "references": [
    {
      "citation_text": "1. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: Knowledge Base, treatment outcomes, and uncertainties. A Rano Review. J Neurosurg. (2015) 122:4-23. doi: 10.3171/2014.7.JNS131644",
      "source_type": "journal",
      "authors": [
        "Rogers L",
        "Barani I",
        "Chamberlain M",
        "Kaley TJ",
        "McDermott M",
        "Raizer J",
        "et al."
      ],
      "title": "Meningiomas: Knowledge Base, treatment outcomes, and uncertainties. A Rano Review.",
      "source_name": "J Neurosurg.",
      "publication_year": 2015,
      "volume": "122",
      "issue": null,
      "pages": "4-23",
      "doi_or_url": "doi: 10.3171/2014.7.JNS131644",
      "confidence": 98
    },
    {
      "citation_text": "2. Zankl H, Zang KD. Cytological and Cytogenetical Studies on Brain Tumors. 4. Identification of the missing G chromosome in human Meningiomas as no. 22 by fluorescence technique. Humangenetik. (1972) 14:167-9. doi: 10.1007/bf00273305",
      "source_type": "journal",
      "authors": [
        "Zankl H",
        "Zang KD"
      ],
      "title": "Cytological and Cytogenetical Studies on Brain Tumors. 4. Identification of the missing G chromosome in human Meningiomas as no. 22 by fluorescence technique.",
      "source_name": "Humangenetik.",
      "publication_year": 1972,
      "volume": "14",
      "issue": null,
      "pages": "167-9",
      "doi_or_url": "doi: 10.1007/bf00273305",
      "confidence": 98
    },
    {
      "citation_text": "3. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the Nf2 gene in the majority of sporadic Meningiomas. Nat Genet. (1994) 6:180-4. doi: 10.1038/ng0294-180",
      "source_type": "journal",
      "authors": [
        "Ruttledge MH",
        "Sarrazin J",
        "Rangaratnam S",
        "Phelan CM",
        "Twist E",
        "Merel P",
        "et al."
      ],
      "title": "Evidence for the complete inactivation of the Nf2 gene in the majority of sporadic Meningiomas.",
      "source_name": "Nat Genet.",
      "publication_year": 1994,
      "volume": "6",
      "issue": null,
      "pages": "180-4",
      "doi_or_url": "doi: 10.1038/ng0294-180",
      "confidence": 98
    },
    {
      "citation_text": "4. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, et al. Screening for mutations in the Neurofibromatosis type 2 (Nf2) gene in sporadic Meningiomas. Hum Genet. (1996) 97:632-7. doi: 10.1007/bf02281874",
      "source_type": "journal",
      "authors": [
        "De Vitis LR",
        "Tedde A",
        "Vitelli F",
        "Ammannati F",
        "Mennonna P",
        "Bigozzi U",
        "et al."
      ],
      "title": "Screening for mutations in the Neurofibromatosis type 2 (Nf2) gene in sporadic Meningiomas.",
      "source_name": "Hum Genet.",
      "publication_year": 1996,
      "volume": "97",
      "issue": null,
      "pages": "632-7",
      "doi_or_url": "doi: 10.1007/bf02281874",
      "confidence": 98
    },
    {
      "citation_text": "5. Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H, et al. Clinical significance of Nf2 alteration in grade I Meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Acta Neuropathol Commun. (2022) 10:76. doi: 10.1186/s40478-022-01377-w",
      "source_type": "journal",
      "authors": [
        "Teranishi Y",
        "Okano A",
        "Miyawaki S",
        "Ohara K",
        "Ishigami D",
        "Hongo H",
        "et al."
      ],
      "title": "Clinical significance of Nf2 alteration in grade I Meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index.",
      "source_name": "Acta Neuropathol Commun.",
      "publication_year": 2022,
      "volume": "10",
      "issue": null,
      "pages": "76",
      "doi_or_url": "doi: 10.1186/s40478-022-01377-w",
      "confidence": 98
    },
    {
      "citation_text": "6. Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, et al. Oncogenic Pi3k mutations are as common as Akt1 and Smo mutations in meningioma. Neuro Oncol. (2016) 18:649-55. doi: 10.1093/neuonc/nov316",
      "source_type": "journal",
      "authors": [
        "Abedalthagafi M",
        "Bi WL",
        "Aizer AA",
        "Merrill PH",
        "Brewster R",
        "Agarwalla PK",
        "et al."
      ],
      "title": "Oncogenic Pi3k mutations are as common as Akt1 and Smo mutations in meningioma.",
      "source_name": "Neuro Oncol.",
      "publication_year": 2016,
      "volume": "18",
      "issue": null,
      "pages": "649-55",
      "doi_or_url": "doi: 10.1093/neuonc/nov316",
      "confidence": 98
    },
    {
      "citation_text": "7. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of Meningiomas identifies oncogenic Smo and Akt1 mutations. Nat Genet. (2013) 45:285-9. doi: 10.1038/ng.2526",
      "source_type": "journal",
      "authors": [
        "Brastianos PK",
        "Horowitz PM",
        "Santagata S",
        "Jones RT",
        "McKenna A",
        "Getz G",
        "et al."
      ],
      "title": "Genomic sequencing of Meningiomas identifies oncogenic Smo and Akt1 mutations.",
      "source_name": "Nat Genet.",
      "publication_year": 2013,
      "volume": "45",
      "issue": null,
      "pages": "285-9",
      "doi_or_url": "doi: 10.1038/ng.2526",
      "confidence": 98
    },
    {
      "citation_text": "8. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-Nf2 Meningiomas reveals mutations in Traf7, Klf4, Akt1, and Smo. Science. (2013) 339:1077-80. doi: 10.1126/science.1233009",
      "source_type": "journal",
      "authors": [
        "Clark VE",
        "Erson-Omay EZ",
        "Serin A",
        "Yin J",
        "Cotney J",
        "Ozduman K",
        "et al."
      ],
      "title": "Genomic analysis of non-Nf2 Meningiomas reveals mutations in Traf7, Klf4, Akt1, and Smo.",
      "source_name": "Science.",
      "publication_year": 2013,
      "volume": "339",
      "issue": null,
      "pages": "1077-80",
      "doi_or_url": "doi: 10.1126/science.1233009",
      "confidence": 98
    },
    {
      "citation_text": "9. Clark VE, Harmanci AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, et al. Recurrent somatic mutations in Polr2a define a distinct subset of Meningiomas. Nat Genet. (2016) 48:1253-9. doi: 10.1038/ng.3651",
      "source_type": "journal",
      "authors": [
        "Clark VE",
        "Harmanci AS",
        "Bai H",
        "Youngblood MW",
        "Lee TI",
        "Baranoski JF",
        "et al."
      ],
      "title": "Recurrent somatic mutations in Polr2a define a distinct subset of Meningiomas.",
      "source_name": "Nat Genet.",
      "publication_year": 2016,
      "volume": "48",
      "issue": null,
      "pages": "1253-9",
      "doi_or_url": "doi: 10.1038/ng.3651",
      "confidence": 98
    },
    {
      "citation_text": "10. Okano A, Miyawaki S, Hongo H, Dofuku S, Teranishi Y, Mitsui J, et al. Associations of pathological diagnosis and genetic abnormalities in Meningiomas with the embryological origins of the meninges. Sci Rep. (2021) 11:6987. doi: 10.1038/s41598-021-86298-9",
      "source_type": "journal",
      "authors": [
        "Okano A",
        "Miyawaki S",
        "Hongo H",
        "Dofuku S",
        "Teranishi Y",
        "Mitsui J",
        "et al."
      ],
      "title": "Associations of pathological diagnosis and genetic abnormalities in Meningiomas with the embryological origins of the meninges.",
      "source_name": "Sci Rep.",
      "publication_year": 2021,
      "volume": "11",
      "issue": null,
      "pages": "6987",
      "doi_or_url": "doi: 10.1038/s41598-021-86298-9",
      "confidence": 98
    },
    {
      "citation_text": "11. Patel AJ, Wan YW, Al-Ouran R, Revelli JP, Cardenas MF, Oneissi M, et al. Molecular profiling predicts meningioma recurrence and reveals loss of dream complex repression in aggressive tumors. Proc Natl Acad Sci US A. (2019) 116:21715-26. doi: 10.1073/pnas.1912858116",
      "source_type": "journal",
      "authors": [
        "Patel AJ",
        "Wan YW",
        "Al-Ouran R",
        "Revelli JP",
        "Cardenas MF",
        "Oneissi M",
        "et al."
      ],
      "title": "Molecular profiling predicts meningioma recurrence and reveals loss of dream complex repression in aggressive tumors.",
      "source_name": "Proc Natl Acad Sci US A.",
      "publication_year": 2019,
      "volume": "116",
      "issue": null,
      "pages": "21715-26",
      "doi_or_url": "doi: 10.1073/pnas.1912858116",
      "confidence": 98
    },
    {
      "citation_text": "12. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis. Lancet Oncol. (2017) 18:682-94. doi: 10.1016/s1470-2045(17)30155-9",
      "source_type": "journal",
      "authors": [
        "Sahm F",
        "Schrimpf D",
        "Stichel D",
        "Jones DTW",
        "Hielscher T",
        "Schefzyk S",
        "et al."
      ],
      "title": "DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis.",
      "source_name": "Lancet Oncol.",
      "publication_year": 2017,
      "volume": "18",
      "issue": null,
      "pages": "682-94",
      "doi_or_url": "doi: 10.1016/s1470-2045(17)30155-9",
      "confidence": 98
    },
    {
      "citation_text": "13. Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. (2019) 21:901-10. doi: 10.1093/neuonc/noz061",
      "source_type": "journal",
      "authors": [
        "Nassiri F",
        "Mamatjan Y",
        "Suppiah S",
        "Badhiwala JH",
        "Mansouri S",
        "Karimi S",
        "et al."
      ],
      "title": "DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.",
      "source_name": "Neuro Oncol.",
      "publication_year": 2019,
      "volume": "21",
      "issue": null,
      "pages": "901-10",
      "doi_or_url": "doi: 10.1093/neuonc/noz061",
      "confidence": 98
    },
    {
      "citation_text": "14. Prager BC, Vasudevan HN, Dixit D, Bernatchez JA, Wu Q, Wallace LC, et al. The meningioma enhancer landscape delineates novel subgroups and drives Druggable dependencies. Cancer Discov. (2020) 10:1722-41. doi: 10.1158/2159-8290.CD-20-0160",
      "source_type": "journal",
      "authors": [
        "Prager BC",
        "Vasudevan HN",
        "Dixit D",
        "Bernatchez JA",
        "Wu Q",
        "Wallace LC",
        "et al."
      ],
      "title": "The meningioma enhancer landscape delineates novel subgroups and drives Druggable dependencies.",
      "source_name": "Cancer Discov.",
      "publication_year": 2020,
      "volume": "10",
      "issue": null,
      "pages": "1722-41",
      "doi_or_url": "doi: 10.1158/2159-8290.CD-20-0160",
      "confidence": 98
    },
    {
      "citation_text": "15. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, et al. Phase ii study of Imatinib Mesylate for recurrent Meningiomas (north American brain tumor consortium study 01-08). Neuro Oncol. (2009) 11:853-60. doi: 10.1215/15228517-2009-010",
      "source_type": "journal",
      "authors": [
        "Wen PY",
        "Yung WK",
        "Lamborn KR",
        "Norden AD",
        "Cloughesy TF",
        "Abrey LE",
        "et al."
      ],
      "title": "Phase ii study of Imatinib Mesylate for recurrent Meningiomas (north American brain tumor consortium study 01-08).",
      "source_name": "Neuro Oncol.",
      "publication_year": 2009,
      "volume": "11",
      "issue": null,
      "pages": "853-60",
      "doi_or_url": "doi: 10.1215/15228517-2009-010",
      "confidence": 98
    },
    {
      "citation_text": "16. Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, et al. Bevacizumab treatment for Meningiomas in Nf2: A retrospective analysis of 15 patients. PLoS One. (2013) 8:e59941. doi: 10.1371/journal.pone.0059941",
      "source_type": "journal",
      "authors": [
        "Nunes FP",
        "Merker VL",
        "Jennings D",
        "Caruso PA",
        "di Tomaso E",
        "Muzikansky A",
        "et al."
      ],
      "title": "Bevacizumab treatment for Meningiomas in Nf2: A retrospective analysis of 15 patients.",
      "source_name": "PLoS One.",
      "publication_year": 2013,
      "volume": "8",
      "issue": null,
      "pages": "e59941",
      "doi_or_url": "doi: 10.1371/journal.pone.0059941",
      "confidence": 98
    },
    {
      "citation_text": "17. Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase ii trial of Sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. (2015) 17:116-21. doi: 10.1093/neuonc/nou148",
      "source_type": "journal",
      "authors": [
        "Kaley TJ",
        "Wen P",
        "Schiff D",
        "Ligon K",
        "Haidar S",
        "Karimi S",
        "et al."
      ],
      "title": "Phase ii trial of Sunitinib for recurrent and progressive atypical and anaplastic meningioma.",
      "source_name": "Neuro Oncol.",
      "publication_year": 2015,
      "volume": "17",
      "issue": null,
      "pages": "116-21",
      "doi_or_url": "doi: 10.1093/neuonc/nou148",
      "confidence": 98
    },
    {
      "citation_text": "18. Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, et al. A phase ii trial of Ptk787/Zk 222584 in recurrent or progressive radiation and surgery refractory Meningiomas. J Neuro Oncol. (2014) 117:93-101. doi: 10.1007/s11060-014-1358-9",
      "source_type": "journal",
      "authors": [
        "Raizer JJ",
        "Grimm SA",
        "Rademaker A",
        "Chandler JP",
        "Muro K",
        "Helenowski I",
        "et al."
      ],
      "title": "A phase ii trial of Ptk787/Zk 222584 in recurrent or progressive radiation and surgery refractory Meningiomas.",
      "source_name": "J Neuro Oncol.",
      "publication_year": 2014,
      "volume": "117",
      "issue": null,
      "pages": "93-101",
      "doi_or_url": "doi: 10.1007/s11060-014-1358-9",
      "confidence": 98
    },
    {
      "citation_text": "19. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al. Phase ii trials of Erlotinib or Gefitinib in patients with recurrent meningioma. J Neuro Oncol. (2010) 96:211-7. doi: 10.1007/s11060-009-9948-7",
      "source_type": "journal",
      "authors": [
        "Norden AD",
        "Raizer JJ",
        "Abrey LE",
        "Lamborn KR",
        "Lassman AB",
        "Chang SM",
        "et al."
      ],
      "title": "Phase ii trials of Erlotinib or Gefitinib in patients with recurrent meningioma.",
      "source_name": "J Neuro Oncol.",
      "publication_year": 2010,
      "volume": "96",
      "issue": null,
      "pages": "211-7",
      "doi_or_url": "doi: 10.1007/s11060-009-9948-7",
      "confidence": 98
    },
    {
      "citation_text": "20. Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the phase ii Cevorem trial. Clin Cancer Res. (2020) 26:552-7. doi: 10.1158/1078-0432.CCR-19-2109",
      "source_type": "journal",
      "authors": [
        "Graillon T",
        "Sanson M",
        "Campello C",
        "Idbaih A",
        "Peyre M",
        "Peyriere H",
        "et al."
      ],
      "title": "Everolimus and octreotide for patients with recurrent meningioma: results from the phase ii Cevorem trial.",
      "source_name": "Clin Cancer Res.",
      "publication_year": 2020,
      "volume": "26",
      "issue": null,
      "pages": "552-7",
      "doi_or_url": "doi: 10.1158/1078-0432.CCR-19-2109",
      "confidence": 98
    },
    {
      "citation_text": "21. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying Nf2 status. Clin Cancer Res. (2010) 16:4155-64. doi: 10.1158/1078-0432.CCR-10-0891",
      "source_type": "journal",
      "authors": [
        "Goutagny S",
        "Yang HW",
        "Zucman-Rossi J",
        "Chan J",
        "Dreyfuss JM",
        "Park PJ",
        "et al."
      ],
      "title": "Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying Nf2 status.",
      "source_name": "Clin Cancer Res.",
      "publication_year": 2010,
      "volume": "16",
      "issue": null,
      "pages": "4155-64",
      "doi_or_url": "doi: 10.1158/1078-0432.CCR-10-0891",
      "confidence": 98
    },
    {
      "citation_text": "22. Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, et al. Erratum: genomic landscape of high-grade Meningiomas. NPJ Genom Med. (2017) 2:26. doi: 10.1038/s41525-017-0023-6",
      "source_type": "journal",
      "authors": [
        "Bi WL",
        "Greenwald NF",
        "Abedalthagafi M",
        "Wala J",
        "Gibson WJ",
        "Agarwalla PK",
        "et al."
      ],
      "title": "Erratum: genomic landscape of high-grade Meningiomas.",
      "source_name": "NPJ Genom Med.",
      "publication_year": 2017,
      "volume": "2",
      "issue": null,
      "pages": "26",
      "doi_or_url": "doi: 10.1038/s41525-017-0023-6",
      "confidence": 98
    },
    {
      "citation_text": "23. Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 Cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. (2019) 110:1480-90. doi: 10.1111/cas.13969",
      "source_type": "journal",
      "authors": [
        "Sunami K",
        "Ichikawa H",
        "Kubo T",
        "Kato M",
        "Fujiwara Y",
        "Shimomura A",
        "et al."
      ],
      "title": "Feasibility and utility of a panel testing for 114 Cancer-associated genes in a clinical setting: A hospital-based study.",
      "source_name": "Cancer Sci.",
      "publication_year": 2019,
      "volume": "110",
      "issue": null,
      "pages": "1480-90",
      "doi_or_url": "doi: 10.1111/cas.13969",
      "confidence": 98
    },
    {
      "citation_text": "24. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Erratum: mutational landscape of metastatic Cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. (2017) 23:1004. doi: 10.1038/nm0817-1004c",
      "source_type": "journal",
      "authors": [
        "Zehir A",
        "Benayed R",
        "Shah RH",
        "Syed A",
        "Middha S",
        "Kim HR",
        "et al."
      ],
      "title": "Erratum: mutational landscape of metastatic Cancer revealed from prospective clinical sequencing of 10,000 patients.",
      "source_name": "Nat Med.",
      "publication_year": 2017,
      "volume": "23",
      "issue": null,
      "pages": "1004",
      "doi_or_url": "doi: 10.1038/nm0817-1004c",
      "confidence": 98
    },
    {
      "citation_text": "25. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto Genomically matched clinical trials. J Clin Oncol. (2015) 33:2753-62. doi: 10.1200/JCO.2014.60.4165",
      "source_type": "journal",
      "authors": [
        "Meric-Bernstam F",
        "Brusco L",
        "Shaw K",
        "Horombe C",
        "Kopetz S",
        "Davies MA",
        "et al."
      ],
      "title": "Feasibility of large-scale genomic testing to facilitate enrollment onto Genomically matched clinical trials.",
      "source_name": "J Clin Oncol.",
      "publication_year": 2015,
      "volume": "33",
      "issue": null,
      "pages": "2753-62",
      "doi_or_url": "doi: 10.1200/JCO.2014.60.4165",
      "confidence": 98
    },
    {
      "citation_text": "26. Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, et al. Comprehensive assay for the molecular profiling of Cancer by target enrichment from formalin-fixed paraffin-embedded specimens. Cancer Sci. (2019) 110:1464-79. doi: 10.1111/cas.13968",
      "source_type": "journal",
      "authors": [
        "Kohsaka S",
        "Tatsuno K",
        "Ueno T",
        "Nagano M",
        "Shinozaki-Ushiku A",
        "Ushiku T",
        "et al."
      ],
      "title": "Comprehensive assay for the molecular profiling of Cancer by target enrichment from formalin-fixed paraffin-embedded specimens.",
      "source_name": "Cancer Sci.",
      "publication_year": 2019,
      "volume": "110",
      "issue": null,
      "pages": "1464-79",
      "doi_or_url": "doi: 10.1111/cas.13968",
      "confidence": 98
    },
    {
      "citation_text": "27. Ando M, Kobayashi H, Shinozaki-Ushiku A, Chikuda H, Matsubayashi Y, Yoshida M, et al. Spinal solitary fibrous tumor of the neck: next-generation sequencing-based analysis of genomic aberrations. Auris Nasus Larynx. (2020) 47:1058-63. doi: 10.1016/j.anl.2019.12.001",
      "source_type": "journal",
      "authors": [
        "Ando M",
        "Kobayashi H",
        "Shinozaki-Ushiku A",
        "Chikuda H",
        "Matsubayashi Y",
        "Yoshida M",
        "et al."
      ],
      "title": "Spinal solitary fibrous tumor of the neck: next-generation sequencing-based analysis of genomic aberrations.",
      "source_name": "Auris Nasus Larynx.",
      "publication_year": 2020,
      "volume": "47",
      "issue": null,
      "pages": "1058-63",
      "doi_or_url": "doi: 10.1016/j.anl.2019.12.001",
      "confidence": 98
    },
    {
      "citation_text": "28. Shinozaki-Ushiku A, Kohsaka S, Kage H, Oda K, Miyagawa K, Nakajima J, et al. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: identification of a novel Bap 1 germline variant. Pathol Int. (2020) 70:775-80. doi: 10.1111/pin.12977",
      "source_type": "journal",
      "authors": [
        "Shinozaki-Ushiku A",
        "Kohsaka S",
        "Kage H",
        "Oda K",
        "Miyagawa K",
        "Nakajima J",
        "et al."
      ],
      "title": "Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: identification of a novel Bap 1 germline variant.",
      "source_name": "Pathol Int.",
      "publication_year": 2020,
      "volume": "70",
      "issue": null,
      "pages": "775-80",
      "doi_or_url": "doi: 10.1111/pin.12977",
      "confidence": 98
    },
    {
      "citation_text": "29. Lorenz J, Rothhammer-Hampl T, Zoubaa S, Bumes E, Pukrop T, Kolbl O, et al. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in Neurooncology. Acta Neuropathol Commun. (2020) 8:124. doi: 10.1186/s40478-020-01000-w",
      "source_type": "journal",
      "authors": [
        "Lorenz J",
        "Rothhammer-Hampl T",
        "Zoubaa S",
        "Bumes E",
        "Pukrop T",
        "Kolbl O",
        "et al."
      ],
      "title": "A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in Neurooncology.",
      "source_name": "Acta Neuropathol Commun.",
      "publication_year": 2020,
      "volume": "8",
      "issue": null,
      "pages": "124",
      "doi_or_url": "doi: 10.1186/s40478-020-01000-w",
      "confidence": 98
    },
    {
      "citation_text": "30. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The Prisma 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. (2021) 10:89. doi: 10.1186/s13643-021-01626-4",
      "source_type": "journal",
      "authors": [
        "Page MJ",
        "McKenzie JE",
        "Bossuyt PM",
        "Boutron I",
        "Hoffmann TC",
        "Mulrow CD",
        "et al."
      ],
      "title": "The Prisma 2020 statement: an updated guideline for reporting systematic reviews.",
      "source_name": "Syst Rev.",
      "publication_year": 2021,
      "volume": "10",
      "issue": null,
      "pages": "89",
      "doi_or_url": "doi: 10.1186/s13643-021-01626-4",
      "confidence": 98
    },
    {
      "citation_text": "31. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al. Analysis of genomic alterations in benign, atypical, and anaplastic Meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci US A. (1997) 94:14719-24. doi: 10.1073/pnas.94.26.14719",
      "source_type": "journal",
      "authors": [
        "Weber RG",
        "Bostrom J",
        "Wolter M",
        "Baudis M",
        "Collins VP",
        "Reifenberger G",
        "et al."
      ],
      "title": "Analysis of genomic alterations in benign, atypical, and anaplastic Meningiomas: toward a genetic model of meningioma progression.",
      "source_name": "Proc Natl Acad Sci US A.",
      "publication_year": 1997,
      "volume": "94",
      "issue": null,
      "pages": "14719-24",
      "doi_or_url": "doi: 10.1073/pnas.94.26.14719",
      "confidence": 98
    },
    {
      "citation_text": "32. Guyot A, Duchesne M, Robert S, Lia AS, Derouault P, Scaon E, et al. Analysis of Cdkn2a gene alterations in recurrent and non-recurrent meningioma. J Neuro Oncol. (2019) 145:449-59. doi: 10.1007/s11060-019-03333-6",
      "source_type": "journal",
      "authors": [
        "Guyot A",
        "Duchesne M",
        "Robert S",
        "Lia AS",
        "Derouault P",
        "Scaon E",
        "et al."
      ],
      "title": "Analysis of Cdkn2a gene alterations in recurrent and non-recurrent meningioma.",
      "source_name": "J Neuro Oncol.",
      "publication_year": 2019,
      "volume": "145",
      "issue": null,
      "pages": "449-59",
      "doi_or_url": "doi: 10.1007/s11060-019-03333-6",
      "confidence": 98
    },
    {
      "citation_text": "33. Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, et al. A clinically applicable integrative molecular classification of Meningiomas. Nature. (2021) 597:119-25. doi: 10.1038/s41586-021-03850-3",
      "source_type": "journal",
      "authors": [
        "Nassiri F",
        "Liu J",
        "Patil V",
        "Mamatjan Y",
        "Wang JZ",
        "Hugh-White R",
        "et al."
      ],
      "title": "A clinically applicable integrative molecular classification of Meningiomas.",
      "source_name": "Nature.",
      "publication_year": 2021,
      "volume": "597",
      "issue": null,
      "pages": "119-25",
      "doi_or_url": "doi: 10.1038/s41586-021-03850-3",
      "confidence": 98
    },
    {
      "citation_text": "34. Harmanci AS, Youngblood MW, Clark VE, Coskun S, Henegariu O, Duran D, et al. Integrated genomic analyses of De novo pathways underlying atypical Meningiomas. Nat Commun. (2017) 8:14433. doi: 10.1038/ncomms14433",
      "source_type": "journal",
      "authors": [
        "Harmanci AS",
        "Youngblood MW",
        "Clark VE",
        "Coskun S",
        "Henegariu O",
        "Duran D",
        "et al."
      ],
      "title": "Integrated genomic analyses of De novo pathways underlying atypical Meningiomas.",
      "source_name": "Nat Commun.",
      "publication_year": 2017,
      "volume": "8",
      "issue": null,
      "pages": "14433",
      "doi_or_url": "doi: 10.1038/ncomms14433",
      "confidence": 98
    },
    {
      "citation_text": "35. Pepe F, Pisapia P, Basso D, de Caro ML, Conticelli F, Malapelle U, et al. Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. Histol Histopathol. (2020) 35:741-9. doi: 10.14670/HH-18-195",
      "source_type": "journal",
      "authors": [
        "Pepe F",
        "Pisapia P",
        "Basso D",
        "de Caro ML",
        "Conticelli F",
        "Malapelle U",
        "et al."
      ],
      "title": "Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.",
      "source_name": "Histol Histopathol.",
      "publication_year": 2020,
      "volume": "35",
      "issue": null,
      "pages": "741-9",
      "doi_or_url": "doi: 10.14670/HH-18-195",
      "confidence": 98
    },
    {
      "citation_text": "36. Williams EA, Santagata S, Wakimoto H, Shankar GM, Barker FG 2nd, Sharaf R, et al. Distinct genomic subclasses of high-grade/progressive Meningiomas: Nf2-associated, Nf2-exclusive, and Nf2-agnostic. Acta Neuropathol Commun. (2020) 8:171. doi: 10.1186/s40478-020-01040-2",
      "source_type": "journal",
      "authors": [
        "Williams EA",
        "Santagata S",
        "Wakimoto H",
        "Shankar GM",
        "Barker FG 2nd",
        "Sharaf R",
        "et al."
      ],
      "title": "Distinct genomic subclasses of high-grade/progressive Meningiomas: Nf2-associated, Nf2-exclusive, and Nf2-agnostic.",
      "source_name": "Acta Neuropathol Commun.",
      "publication_year": 2020,
      "volume": "8",
      "issue": null,
      "pages": "171",
      "doi_or_url": "doi: 10.1186/s40478-020-01040-2",
      "confidence": 98
    },
    {
      "citation_text": "37. Simpson D. The recurrence of intracranial Meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. (1957) 20:22-39. doi: 10.1136/jnnp.20.1.22",
      "source_type": "journal",
      "authors": [
        "Simpson D"
      ],
      "title": "The recurrence of intracranial Meningiomas after surgical treatment.",
      "source_name": "J Neurol Neurosurg Psychiatry.",
      "publication_year": 1957,
      "volume": "20",
      "issue": "1",
      "pages": "22-39",
      "doi_or_url": "doi: 10.1136/jnnp.20.1.22",
      "confidence": 98
    },
    {
      "citation_text": "38. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, et al. Phase ii study of Gleevec(R) plus hydroxyurea (Hu) in adults with progressive or recurrent meningioma. J Neuro Oncol. (2012) 106:409-15. doi: 10.1007/s11060-011-0687-1",
      "source_type": "journal",
      "authors": [
        "Reardon DA",
        "Norden AD",
        "Desjardins A",
        "Vredenburgh JJ",
        "Herndon JE 2nd",
        "Coan A",
        "et al."
      ],
      "title": "Phase ii study of Gleevec(R) plus hydroxyurea (Hu) in adults with progressive or recurrent meningioma.",
      "source_name": "J Neuro Oncol.",
      "publication_year": 2012,
      "volume": "106",
      "issue": null,
      "pages": "409-15",
      "doi_or_url": "doi: 10.1007/s11060-011-0687-1",
      "confidence": 98
    },
    {
      "citation_text": "39. Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, et al. A phase ii trial of bevacizumab and Everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neuro Oncol. (2016) 129:281-8. doi: 10.1007/s11060-016-2172-3",
      "source_type": "journal",
      "authors": [
        "Shih KC",
        "Chowdhary S",
        "Rosenblatt P",
        "Weir AB 3rd",
        "Shepard GC",
        "Williams JT",
        "et al."
      ],
      "title": "A phase ii trial of bevacizumab and Everolimus as treatment for patients with refractory, progressive intracranial meningioma.",
      "source_name": "J Neuro Oncol.",
      "publication_year": 2016,
      "volume": "129",
      "issue": null,
      "pages": "281-8",
      "doi_or_url": "doi: 10.1007/s11060-016-2172-3",
      "confidence": 98
    },
    {
      "citation_text": "40. Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, et al. Phase 2 study of Pembrolizumab in patients with recurrent and residual high-grade Meningiomas. Nat Commun. (2022) 13:1325. doi: 10.1038/s41467-022-29052-7",
      "source_type": "journal",
      "authors": [
        "Brastianos PK",
        "Kim AE",
        "Giobbie-Hurder A",
        "Lee EQ",
        "Wang N",
        "Eichler AF",
        "et al."
      ],
      "title": "Phase 2 study of Pembrolizumab in patients with recurrent and residual high-grade Meningiomas.",
      "source_name": "Nat Commun.",
      "publication_year": 2022,
      "volume": "13",
      "issue": null,
      "pages": "1325",
      "doi_or_url": "doi: 10.1038/s41467-022-29052-7",
      "confidence": 98
    },
    {
      "citation_text": "41. Bi WL, Nayak L, Meredith DM, Driver J, Du Z, Hoffman S, et al. Activity of Pd-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: phase ii trial results. Neuro Oncol. (2022) 24:101-13. doi: 10.1093/neuonc/noab118",
      "source_type": "journal",
      "authors": [
        "Bi WL",
        "Nayak L",
        "Meredith DM",
        "Driver J",
        "Du Z",
        "Hoffman S",
        "et al."
      ],
      "title": "Activity of Pd-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: phase ii trial results.",
      "source_name": "Neuro Oncol.",
      "publication_year": 2022,
      "volume": "24",
      "issue": null,
      "pages": "101-13",
      "doi_or_url": "doi: 10.1093/neuonc/noab118",
      "confidence": 98
    },
    {
      "citation_text": "42. Kumthekar P, Grimm SA, Aleman RT, Chamberlain MC, Schiff D, Wen PY, et al. A multi-institutional phase ii trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. (2022) 4:123. doi: 10.1093/noajnl/vdac123",
      "source_type": "journal",
      "authors": [
        "Kumthekar P",
        "Grimm SA",
        "Aleman RT",
        "Chamberlain MC",
        "Schiff D",
        "Wen PY",
        "et al."
      ],
      "title": "A multi-institutional phase ii trial of bevacizumab for recurrent and refractory meningioma.",
      "source_name": "Neurooncol Adv.",
      "publication_year": 2022,
      "volume": "4",
      "issue": null,
      "pages": "123",
      "doi_or_url": "doi: 10.1093/noajnl/vdac123",
      "confidence": 98
    },
    {
      "citation_text": "43. Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, et al. Alliance A071401: phase ii trial of focal adhesion kinase inhibition in Meningiomas with somatic Nf2 mutations. J Clin Oncol. (2023) 41:618-28. doi: 10.1200/JCO.21.02371",
      "source_type": "journal",
      "authors": [
        "Brastianos PK",
        "Twohy EL",
        "Gerstner ER",
        "Kaufmann TJ",
        "Iafrate AJ",
        "Lennerz J",
        "et al."
      ],
      "title": "Alliance A071401: phase ii trial of focal adhesion kinase inhibition in Meningiomas with somatic Nf2 mutations.",
      "source_name": "J Clin Oncol.",
      "publication_year": 2023,
      "volume": "41",
      "issue": null,
      "pages": "618-28",
      "doi_or_url": "doi: 10.1200/JCO.21.02371",
      "confidence": 98
    },
    {
      "citation_text": "44. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, et al. Advances in multidisciplinary therapy for Meningiomas. Neuro Oncol. (2019) 21:118-31. doi: 10.1093/neuonc/noy136",
      "source_type": "journal",
      "authors": [
        "Brastianos PK",
        "Galanis E",
        "Butowski N",
        "Chan JW",
        "Dunn IF",
        "Goldbrunner R",
        "et al."
      ],
      "title": "Advances in multidisciplinary therapy for Meningiomas.",
      "source_name": "Neuro Oncol.",
      "publication_year": 2019,
      "volume": "21",
      "issue": null,
      "pages": "118-31",
      "doi_or_url": "doi: 10.1093/neuonc/noy136",
      "confidence": 98
    },
    {
      "citation_text": "45. Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet. (2022) 54:649-59. doi: 10.1038/s41588-022-01061-8",
      "source_type": "journal",
      "authors": [
        "Choudhury A",
        "Magill ST",
        "Eaton CD",
        "Prager BC",
        "Chen WC",
        "Cady MA",
        "et al."
      ],
      "title": "Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.",
      "source_name": "Nat Genet.",
      "publication_year": 2022,
      "volume": "54",
      "issue": null,
      "pages": "649-59",
      "doi_or_url": "doi: 10.1038/s41588-022-01061-8",
      "confidence": 98
    },
    {
      "citation_text": "46. Paramasivam N, Hübschmann D, Toprak UH, Ishaque N, Neidert M, Schrimpf D, et al. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol. (2019) 138:295-308. doi: 10.1007/s00401-019-02008-w",
      "source_type": "journal",
      "authors": [
        "Paramasivam N",
        "Hübschmann D",
        "Toprak UH",
        "Ishaque N",
        "Neidert M",
        "Schrimpf D",
        "et al."
      ],
      "title": "Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.",
      "source_name": "Acta Neuropathol.",
      "publication_year": 2019,
      "volume": "138",
      "issue": null,
      "pages": "295-308",
      "doi_or_url": "doi: 10.1007/s00401-019-02008-w",
      "confidence": 98
    }
  ]
}